AUTHOR=Lu Linbin , Fang Wenzheng , Yu Jun , Gao Xianchun , Wang Xinlin , Pan Yan , Han Weili , Yan Junya , Xie Huahong , Yao Liping , Yang Jianjun , Zheng Jianyong , Hong Liu , Li Jipeng , Li Mengbin , Shang Lei , Wu Kaichun , Ji Gang , Nie Yongzhan 

TITLE=Development and validation of serological dynamic risk score to predict outcome in gastric cancer with adjuvant chemotherapy: a multicentre, longitudinal, cohort study

JOURNAL=Frontiers in Oncology

VOLUME=Volume 14 - 2024

YEAR=2024

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1327691

DOI=10.3389/fonc.2024.1327691

ISSN=2234-943X

ABSTRACT=Baseline serological biomarkers have the potential to predict the benefits of adjuvant chemotherapy in patients with gastric cancer. However, the fluctuating nature of postoperative recurrence risk makes precise treatment challenging. We aimed to develop a risk score in real-time predicting outcomes for postoperative GC patients using blood chemistry tests.This was a retrospective, multicenter, longitudinal cohort study from three cancer centers in China, with a total of 2737 GC patients in the pTNM stage Ⅰb to Ⅲ. Among them, 1651 patients with at least two serological records were assigned to the training cohort. Model validation was carried out using separate testing data with area under curve (AUC). The least absolute shrinkage and selection operator (LASSO) and random forest-recursive feature elimination (RF-RFE) algorithm were used to select the parameters.The Cox regression model derived six risk factors to construct a composite score (low-risk: 0-2 score; high risk: 3-6 score), including CEA, CA125, CA199, hemoglobin, albumin, and neutrophil to lymphocyte ratio. The risk score accurately predicted mortality in 1000-time bootstrap (AUROCs:0.658; 95% CI: 0.645, 0.670), with the highest AUROC (0.767; 95% CI: 0.743, 0.791) after 1 year since the gastrectomy. In validation dataset, the risk score had an AUROC of 0.586 (95% CI 0.544, 0.628).Furthermore, patients with high risk at 1 month derived significant clinical benefits from adjuvant chemotherapy (P for interaction <0.0001). Compared with the low-low-low risk group, the low-lowhigh risk group of the long-term state chain (risk state at baseline, 6 months, 1 year) had the worse